GeNeuro SA Company Profile

20:30 EDT 23rd March 2018 | BioPortfolio

News Articles [13 Associated News Articles listed on BioPortfolio]

GeNeuro: Annual Report on the Liquidity Contract with Gilbert Dupont

Market: Euronext ParisISIN code Mnemo: CH0308403085 GNROWeb site: Regulatory News: Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of ...

FDA orphan status given to Geneuro's CIDP therapy

Geneuro's GNBAC1 was given orphan drug status by the FDA as a treatment for patients with chronic inflammatory demyelinating  -More- 

GeNeuro to Host Conference Call and Webcast Today Following the Presentation of Promising Post-Hoc Analyses at the MSParis2017 Congress

Conference call and webcast scheduled today at 2:00 pm CET 09:00 am EDT Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neur...

GeNeuro Reports Cash and Revenue for Q3 2017

Cash position of €16.4 million as of 30 September 2017 €12 million milestone from Servier expected by end 2017 Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 GNRO), a biopharm...

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro dev...

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro’s stock rose by 30% on Monday followin...

GeNeuro Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

GNbAC1 targets pHERV-W env, which is found in half of CIDP patients Forthcoming discussions expected with the FDA for the design of a proof-of-concept Phase 2 clinical study Regulatory News: GeNeu...

GeNeuro SA GNRO Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryGeNeuro SA GeNeuro is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflamm...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


GeNeuro is a Swiss-based company created by Eclosion in 2006 as a spin-off of bioMérieux and co-funded by Eclosion and the Institut Mérieux. GeNeuro is developing first-in-c...

GeNeuro SA

More Information about "GeNeuro SA" on BioPortfolio

We have published hundreds of GeNeuro SA news stories on BioPortfolio along with dozens of GeNeuro SA Clinical Trials and PubMed Articles about GeNeuro SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GeNeuro SA Companies in our database. You can also find out about relevant GeNeuro SA Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record